收藏切换
Key points and analysis for on-site verification of drug clinical trial data after the implementation of the 2020 ‘Good Clinical Practice’
收藏切换
PDF
Li-ya CAO, Lin-li XIE, Jiang-chuan XIE, Xin-mei PAN, Pan MA, Yong-chuan CHEN
Chinese Journal of New Drugs | 2023, 32(3) : 264 - 269
Less
收藏切换
Chinese Journal of New Drugs | 2023, 32(3): 264-269
Key points and analysis for on-site verification of drug clinical trial data after the implementation of the 2020 ‘Good Clinical Practice’
Full
Li-ya CAO, Lin-li XIE, Jiang-chuan XIE, Xin-mei PAN, Pan MA, Yong-chuan CHEN
Affiliations
  • Department of Pharmacy, First Affiliated Hospital of Army Medical University, PLA, Chongqing 400038, China
Published: 2023-02-15
Outline
收藏切换
Objective:

To sort out the previous on-site inspection of clinical trial data by the Center for Food and Drug Inspection (CFDI) of National Medical Products Administration (NMPA), to analyze and discuss the concerns and requirements of common problems in on-site inspection of drug clinical trial data after the implementation of the 2020 Good Clinic Practice (GCP), and to provide reference for the implementation and management of clinical trials.

Methods:

We collected unqualified situation of the on-site verification of hospital's acceptance of CFDI data since July 22, 2015. A total of 21 items of clinical trials were included, among which 135 items were unqualified. For the common problems in the past non-conformities, the concerns and requirements of the 2020 version of GCP and on-site inspection were analyzed.

Results:

The previous unqualified items mainly focused on process records, as well as inspection and inspection of data traceability, program execution, safety event records, management and records of investigational drugs, biological sample circulation management, and the integrity of related data chains. The 2020 GCP and on-site verification points were quite different from the previous requirements regarding common problems in on-site verification of clinical trial data.

Conclusion:

Under this new situation, it is necessary to change the previous concepts and rules, and carry out drug clinical trials according to the concerns and requirements of the 2020 version of GCP and the data on-site verification of drug clinical trials.

clinical trial  /  Good Clinical Practice  /  drug registration verification  /  quality management
Li-ya CAO, Lin-li XIE, Jiang-chuan XIE, Xin-mei PAN, Pan MA, Yong-chuan CHEN. Key points and analysis for on-site verification of drug clinical trial data after the implementation of the 2020 ‘Good Clinical Practice’[J]. Chinese Journal of New Drugs, 2023 , 32 (3) : 264 -269 .
Year 2023 volume 32 Issue 3
PDF
31
11
Cite this Article
BibTeX
Article Info
  • Online Date:2026-03-05
  • Published:2023-02-15
Article Data
Affiliations
History
  • Accepted:2022-06-06
Affiliations
    Department of Pharmacy, First Affiliated Hospital of Army Medical University, PLA, Chongqing 400038, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT